{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:18Z","timestamp":1785465138886,"version":"3.56.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"29","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Conventional immune checkpoint inhibitors (ICIs) remain largely ineffective in microsatellite-stable metastatic colorectal cancer (MSS mCRC), where low tumor immunogenicity and molecular heterogeneity across metastatic sites underpin therapeutic resistance. We present a comprehensive transcriptomics analysis of metastatic and primary tumor biopsies from MSS mCRC patients treated with botensilimab (BOT; Fc-enhanced anti\u2013\n                    <jats:italic>CTLA-4<\/jats:italic>\n                    ) \u00b1 balstilimab (BAL; anti\u2013\n                    <jats:italic>PD-1)<\/jats:italic>\n                    . Self-organizing map (SOM) machine learning stratified tumors into four molecular types, including a liver-like (LIV) subtype characterized by metabolic reprogramming and immunosuppressive signatures, and proliferative (PRO), inflammatory (INF), and mesenchymal (MES) types concordant with pan-cancer classifications. PRO, INF, and MES types were enriched for epithelial tumor cells, immune cells, and fibroblasts, respectively, defining immune-depleted, immune-enriched, and fibrotic states along a plasticity gradient. We observed treatment-related transcriptomic shifts toward immune-enriched states via upregulation of antigen presentation, T cell recruitment, and cytotoxicity pathways. INF and MES tumor types exhibited improved clinical responses and survival vs PRO and LIV types. This study identified distinct tumor microenvironment states that align along an immunophenotype axis marked by CD74, interferon-\u03b3, and\n                    <jats:italic>APOBEC3<\/jats:italic>\n                    expression identified previously for primary CRC. Our findings provide novel insights into molecular correlates of immunotherapy response in MSS mCRC, potentially informing future therapeutic strategies to expand ICI efficacy to historically unresponsive tumors.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03861-2","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:38:23Z","timestamp":1781563103000},"page":"2932-2944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-6092","authenticated-orcid":false,"given":"Tomas","family":"Konecny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate","family":"Zadirako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7556-9680","authenticated-orcid":false,"given":"Arpine","family":"Grigoryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7238-2315","authenticated-orcid":false,"given":"Melina","family":"Tamazyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveta","family":"Mnatsakanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Stepanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Loeffler-Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bourdelais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mednick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-9583","authenticated-orcid":false,"given":"Chloe","family":"Delepine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8124-4399","authenticated-orcid":false,"given":"Dhan","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2242-4678","authenticated-orcid":false,"given":"Hans","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"3861_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338\u201344.","journal-title":"Gut"},{"key":"3861_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0043-1761447","volume":"37","author":"MIM Ilyas","year":"2024","unstructured":"Ilyas MIM. Epidemiology of stage IV colorectal cancer: trends in the incidence, prevalence, age distribution, and impact on life span. Clin Colon Rectal Surg. 2024;37:57\u201361.","journal-title":"Clin Colon Rectal Surg"},{"key":"3861_CR3","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"3861_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00353-4","volume":"7","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Oncol. 2023;7:16.","journal-title":"npj Precis Oncol"},{"key":"3861_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277\u201384.","journal-title":"Ann Oncol"},{"key":"3861_CR6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"3861_CR7","doi-asserted-by":"crossref","unstructured":"Gandini A, Puglisi S, Pirrone C, Martelli V, Catalano F, Nardin S, et al. The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives. Front Oncol. 2023;13:2023.","DOI":"10.3389\/fonc.2023.1161048"},{"key":"3861_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JCO.2025.43.4_suppl.207","volume":"43","author":"E Hissong","year":"2025","unstructured":"Hissong E, Jafari MD, Khan S, Kasi PM, Guniganti P, Ocean AJ, et al. Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update. J Clin Oncol. 2025;43:207\u2013207.","journal-title":"J Clin Oncol"},{"key":"3861_CR9","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med. 2024;30:2558\u201367.","journal-title":"Nat Med"},{"key":"3861_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","volume":"14","author":"D Chand","year":"2024","unstructured":"Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, et al. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy. Cancer Discov. 2024;14:2407\u201329.","journal-title":"Cancer Discov"},{"key":"3861_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO-24-02524","volume":"43","author":"BA Wilky","year":"2025","unstructured":"Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, et al. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed\/Refractory Metastatic Sarcomas. J Clin Oncol. 2025;43:1358\u201368.","journal-title":"J Clin Oncol"},{"key":"3861_CR12","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","volume":"42","author":"PM Kasi","year":"2023","unstructured":"Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, et al. Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene. 2023;42:3252\u20139.","journal-title":"Oncogene"},{"key":"3861_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF00337288","volume":"43","author":"T Kohonen","year":"1982","unstructured":"Kohonen T. Self-organized formation of topologically correct feature maps. Biol Cybern. 1982;43:59\u201369. https:\/\/doi.org\/10.1007\/BF00337288.","journal-title":"Biol Cybern"},{"key":"3861_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-306","volume":"12","author":"H Wirth","year":"2011","unstructured":"Wirth H, L\u00f6ffler M, von Bergen M, Binder H. Expression cartography of human tissues using self organizing maps. BMC Bioinforma. 2011;12:306.","journal-title":"BMC Bioinforma"},{"key":"3861_CR15","doi-asserted-by":"crossref","unstructured":"Binder H, Hopp L, Lembcke K, Wirth H. Personalized disease phenotypes from massive OMICs data. In: Baoying W, Ruowang L, William P, editors. Big data analytics in bioinformatics and healthcare. Hershey, PA, USA; IGI Global: 2015, pp. 359\u201378.","DOI":"10.4018\/978-1-4666-6611-5.ch015"},{"key":"3861_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0381-5-18","volume":"5","author":"H Wirth","year":"2012","unstructured":"Wirth H, von Bergen M, Binder H. Mining SOM expression portraits: feature selection and integrating concepts of molecular function. BioData Min. 2012;5:18.","journal-title":"BioData Min"},{"key":"3861_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4161\/sysb.25897","volume":"1","author":"L Hopp","year":"2013","unstructured":"Hopp L, Wirth H, Fasold M, Binder H. Portraying the expression landscapes of cancer subtypes: a glioblastoma multiforme and prostate cancer case study. Syst Biomed. 2013;1:99\u2013121.","journal-title":"Syst Biomed"},{"key":"3861_CR18","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.3390\/cancers14143434","volume":"14","author":"H Loeffler-Wirth","year":"2022","unstructured":"Loeffler-Wirth H, Kreuz M, Schmidt M, Ott G, Siebert R, Binder H. Classifying germinal center derived lymphomas-navigate a complex transcriptional landscape. Cancers. 2022;14:3434.","journal-title":"Cancers"},{"key":"3861_CR19","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3390\/cancers13133198","volume":"13","author":"E Willscher","year":"2021","unstructured":"Willscher E, Hopp L, Kreuz M, Schmidt M, Hakobyan S, Arakelyan A, et al. High-resolution cartography of the transcriptome and methylome landscapes of diffuse gliomas. Cancers. 2021;13:3198.","journal-title":"Cancers"},{"key":"3861_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0637-7","volume":"11","author":"H Loeffler-Wirth","year":"2019","unstructured":"Loeffler-Wirth H, Kreuz M, Hopp L, Arakelyan A, Haake A, Cogliatti SB, et al. A modular transcriptome map of mature B cell lymphomas. Genome Med. 2019;11:27.","journal-title":"Genome Med"},{"key":"3861_CR21","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41388-018-0385-y","volume":"37","author":"M Kunz","year":"2018","unstructured":"Kunz M, L\u00f6ffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, et al. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene. 2018;37:6136\u201351.","journal-title":"Oncogene"},{"key":"3861_CR22","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/cancers15153835","volume":"15","author":"O Ashekyan","year":"2023","unstructured":"Ashekyan O, Shahbazyan N, Bareghamyan Y, Kudryavzeva A, Mandel D, Schmidt M, et al. Transcriptomic maps of colorectal liver metastasis: machine learning of gene activation patterns and epigenetic trajectories in support of precision medicine. Cancers. 2023;15:3835.","journal-title":"Cancers"},{"key":"3861_CR23","doi-asserted-by":"crossref","unstructured":"Schmidt M, Hopp L, Arakelyan A, Kirsten H, Engel C, Wirkner K, et al. The human blood transcriptome in a large population cohort and its relation to aging and health. Front Big Data. 2020;3:548873.","DOI":"10.3389\/fdata.2020.548873"},{"key":"3861_CR24","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1093\/bioinformatics\/btv342","volume":"31","author":"H L\u00f6ffler-Wirth","year":"2015","unstructured":"L\u00f6ffler-Wirth H, Kalcher M, Binder H. oposSOM: R-package for high-dimensional portraying of genome-wide expression landscapes on bioconductor. Bioinformatics. 2015;31:3225\u20137.","journal-title":"Bioinformatics"},{"key":"3861_CR25","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cimb46050284","volume":"46","author":"M Schmidt","year":"2024","unstructured":"Schmidt M, Avagyan S, Reiche K, Binder H, Loeffler-Wirth H. A Spatial Transcriptomics Browser for Discovering Gene Expression Landscapes across Microscopic Tissue Sections. Curr Issues Mol Biol. 2024;46:4701\u20134720.","journal-title":"Curr Issues Mol Biol"},{"key":"3861_CR26","first-page":"773","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F. et al. Determining cell type abundance andexpression from bulk tissues with digital cytometry. Cell. 2019;37:773\u2013782.","journal-title":"Cell"},{"key":"3861_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca BA, Steen CB, Matusiak M, Azizi AJ, Varma S, Zhu C. et al. Atlas of clinically distinct cell states and ecosystemsacross human solid tumors. Cell. 2021;184:773\u20135496.e5428.","journal-title":"Cell"},{"key":"3861_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"3861_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JillP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"3861_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06316-6","volume":"23","author":"J Shang","year":"2025","unstructured":"Shang J, Jiang H, Zhao Y, Yang J, Lin Y, Zhang N, et al. Molecular subtyping of stage I lung adenocarcinoma via molecular alterations in pre-invasive lesion progression. J Transl Med. 2025;23:263.","journal-title":"J Transl Med"},{"key":"3861_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10792-8","volume":"23","author":"W Dai","year":"2023","unstructured":"Dai W, Guo C, Wang Y, Li Y, Xie R, Wu J, et al. Identification of hub genes and pathways in lung metastatic colorectal cancer. BMC Cancer. 2023;23:323.","journal-title":"BMC Cancer"},{"key":"3861_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32198-z","volume":"13","author":"KJ Lenos","year":"2022","unstructured":"Lenos KJ, Bach S, Ferreira Moreno L, ten Hoorn S, Sluiter NR, Bootsma S, et al. Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nat Commun. 2022;13:4443.","journal-title":"Nat Commun"},{"key":"3861_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/(SICI)1096-9896(200005)191:1<21::AID-PATH581>3.0.CO;2-S","volume":"191","author":"K Yun","year":"2000","unstructured":"Yun K, Merrie AEH, Gunn J, Phillips LV, McCall JL. Keratin 20 is a specific marker of submicroscopic lymph node metastases in colorectal cancer: validation by K-RAS mutations. J Pathol. 2000;191:21\u20136.","journal-title":"J Pathol"},{"key":"3861_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12672-024-01404-3","volume":"15","author":"X Feng","year":"2024","unstructured":"Feng X, Wang Q. Keratin-15 high expression links with lymph node metastasis and poor survival prognosis in epithelial ovarian cancer patients. Discov Oncol. 2024;15:555.","journal-title":"Discov Oncol"},{"key":"3861_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63366-4","volume":"14","author":"YJ Ha","year":"2024","unstructured":"Ha YJ, Park S-H, Tak KH, Lee JL, Kim CW, Kim J-H, et al. CILP2 is a potential biomarker for the prediction and therapeutic target of peritoneal metastases in colorectal cancer. Sci Rep. 2024;14:12487.","journal-title":"Sci Rep"},{"key":"3861_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","volume":"43","author":"A Acha-Sagredo","year":"2025","unstructured":"Acha-Sagredo A, Andrei P, Clayton K, Taggart E, Antoniotti C, Woodman CA, et al. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell. 2025;43:292\u2013.e297.","journal-title":"Cancer Cell"},{"key":"3861_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178337","volume":"14","author":"P Chaintreuil","year":"2023","unstructured":"Chaintreuil P, Kerreneur E, Bourgoin M, Savy C, Favreau C, Robert G, et al. The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. Front Immunol. 2023;14:1178337.","journal-title":"Front Immunol"},{"key":"3861_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845\u201365.e847.","journal-title":"Cancer Cell"},{"key":"3861_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100932","volume":"4","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen F, Creighton CJ. Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs. Cell Rep Med. 2023;4:100932.","journal-title":"Cell Rep Med"},{"key":"3861_CR40","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350\u20136.","journal-title":"Nat Med"},{"key":"3861_CR41","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","volume":"29","author":"M Thibaudin","year":"2023","unstructured":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial. Nat Med. 2023;29:2087\u201398.","journal-title":"Nat Med"},{"key":"3861_CR42","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","volume":"29","author":"J Roelands","year":"2023","unstructured":"Roelands J, Kuppen PJK, Ahmed EI, Mall R, Masoodi T, Singh P, et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat Med. 2023;29:1273\u201386.","journal-title":"Nat Med"},{"key":"3861_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e12191","volume":"8","author":"T Peng","year":"2022","unstructured":"Peng T, Liu B, Lin S, Cao C, Wu P, Zhi W, et al. APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. Heliyon. 2022;8:e12191.","journal-title":"Heliyon"},{"key":"3861_CR44","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cancers14122827","volume":"14","author":"H Guo","year":"2022","unstructured":"Guo H, Zhu L, Huang L, Sun Z, Zhang H, Nong B, et al. APOBEC alteration contributes to tumor growth and immune escape in pan-cancer. Cancers. 2022;14:2827.","journal-title":"Cancers"},{"key":"3861_CR45","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/1541-7786.MCR-21-0219","volume":"19","author":"K Zhao","year":"2021","unstructured":"Zhao K, Zhang Q, Flanagan SA, Lang X, Jiang L, Parsels LA, et al. Cytidine deaminase APOBEC3A regulates PD-L1 expression in cancer cells in a JNK\/c-JUN-dependent manner. Mol Cancer Res. 2021;19:1571\u201382.","journal-title":"Mol Cancer Res"},{"key":"3861_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"3861_CR47","doi-asserted-by":"publisher","first-page":"e1284719","DOI":"10.1080\/2162402X.2017.1284719","volume":"6","author":"A Boichard","year":"2017","unstructured":"Boichard A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. OncoImmunology. 2017;6:e1284719.","journal-title":"OncoImmunology"},{"key":"3861_CR48","doi-asserted-by":"publisher","first-page":"1550341","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2019","unstructured":"Boichard A, Pham TV, Huwate Y, Aaron G, Pablo T, Scott L, et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. OncoImmunology. 2019;8:1550341.","journal-title":"OncoImmunology"},{"key":"3861_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcab005","volume":"3","author":"C Roufas","year":"2021","unstructured":"Roufas C, Georgakopoulos-Soares I, Zaravinos A. Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. NAR cancer. 2021;3:zcab005.","journal-title":"NAR cancer"},{"key":"3861_CR50","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.tig.2021.07.003","volume":"37","author":"K Cervantes-Gracia","year":"2021","unstructured":"Cervantes-Gracia K, Gramalla-Schmitz A, Weischedel J, Chahwan R. APOBECs orchestrate genomic and epigenomic editing across health and disease. Trends Genet. 2021;37:1028\u201343.","journal-title":"Trends Genet"},{"key":"3861_CR51","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.virol.2007.06.010","volume":"367","author":"EG Argyris","year":"2007","unstructured":"Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, et al. The interferon-induced expression of APOBEC3G in human blood\u2013brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology. 2007;367:440\u201351.","journal-title":"Virology"},{"key":"3861_CR52","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.jid.2021.12.019","volume":"142","author":"L Que","year":"2022","unstructured":"Que L, Li Y, Dainichi T, Kukimoto I, Nishiyama T, Nakano Y, et al. IFN-\u03b3\u2012induced APOBEC3B contributes to merkel cell polyomavirus genome mutagenesis in merkel cell carcinoma. J Invest Dermatol. 2022;142:1793\u2013803.e1711.","journal-title":"J Invest Dermatol"},{"key":"3861_CR53","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-20-1888","volume":"27","author":"RG Vile","year":"2021","unstructured":"Vile RG, Melcher A, Pandha H, Harrington KJ, Pulido JS. APOBEC and cancer viroimmunotherapy: thinking the unthinkable. Clin Cancer Res. 2021;27:3280\u201390.","journal-title":"Clin Cancer Res"},{"key":"3861_CR54","doi-asserted-by":"crossref","unstructured":"Lehle J, Soleimanpour M, Mokhtari S, Ebrahimi D. Viral infection, APOBEC3 dysregulation, and cancer. Front Genet. 2024;15:1489324.","DOI":"10.3389\/fgene.2024.1489324"},{"key":"3861_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"3861_CR56","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-022-04398-6","volume":"602","author":"EN Bergstrom","year":"2022","unstructured":"Bergstrom EN, Luebeck J, Petljak M, Khandekar A, Barnes M, Zhang T, et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature. 2022;602:510\u20137.","journal-title":"Nature"},{"key":"3861_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1423-0127-18-36","volume":"18","author":"CH Lin","year":"2011","unstructured":"Lin CH, Lin JK, Chang SC, Chang YH, Chang HM, Liu JH, et al. Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan. J Biomed Sci. 2011;18:36.","journal-title":"J Biomed Sci"},{"key":"3861_CR58","doi-asserted-by":"crossref","unstructured":"Debattista J, Grech L, Scerri C, Grech G. Copy number variations as determinants of colorectal tumor progression in liquid biopsies. Int J Mol Sci. 2023;24:1738.","DOI":"10.3390\/ijms24021738"},{"key":"3861_CR59","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41416-022-01913-4","volume":"127","author":"YH Jan","year":"2022","unstructured":"Jan YH, Tan KT, Chen SJ, Yip TTC, Lu CT, Lam AK. Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing. Br J Cancer. 2022;127:1304\u201311.","journal-title":"Br J Cancer"},{"key":"3861_CR60","doi-asserted-by":"publisher","first-page":"e92553","DOI":"10.1371\/journal.pone.0092553","volume":"9","author":"NZ Ali Hassan","year":"2014","unstructured":"Ali Hassan NZ, Mokhtar NM, Kok Sin T, Mohamed Rose I, Sagap I, Harun R, et al. Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues. PLOS ONE. 2014;9:e92553.","journal-title":"PLOS ONE"},{"key":"3861_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58413-1","volume":"16","author":"MM Golas","year":"2025","unstructured":"Golas MM, Gunawan B, Gutenberg A, Danner BC, Gerdes JS, Stadelmann C, et al. Cytogenetic signatures favoring metastatic organotropism in colorectal cancer. Nat Commun. 2025;16:3261.","journal-title":"Nat Commun"},{"key":"3861_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15692-8","volume":"12","author":"CV Rao","year":"2022","unstructured":"Rao CV, Xu C, Zhang Y, Asch AS, Yamada HY. Genomic instability genes in lung and colon adenocarcinoma indicate organ specificity of transcriptomic impact on Copy Number Alterations. Sci Rep. 2022;12:11739.","journal-title":"Sci Rep"},{"key":"3861_CR63","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","volume":"637","author":"AR Moorman","year":"2024","unstructured":"Moorman AR, Benitez EK, Cambuli F, Jiang Q, Mahmoud A, Lumish M. et al. Progressive plasticity during colorectal cancer metastasis. Nature. 2024;637:947\u2013954.","journal-title":"Nature"},{"key":"3861_CR64","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-025-09125-5","volume":"644","author":"P Cammareri","year":"2025","unstructured":"Cammareri P, Raponi M, Hong Y, Billard CV, Peckett N, Zhu Y. et al.Loss of colonic fidelity enablesmultilineage plasticity and metastasis.Nature. 2025;644:547\u2013556.","journal-title":"Nature"},{"key":"3861_CR65","doi-asserted-by":"crossref","unstructured":"Hebenstreit D, Fang M, Gu M, Charoensawan V, van Oudenaarden A, Teichmann SA.. RNA sequencing reveals two major classes of gene expression levels in metazoan cells. Mol Syst Biol. 2011;7:.","DOI":"10.1038\/msb.2011.28"},{"key":"3861_CR66","first-page":"56","volume":"19","author":"M Schmidt","year":"2021","unstructured":"Schmidt M, Mortensen LS, Loeffler-Wirth H, Kosnopfel C, Krohn K, Binder H. et al. Single-cell trajectories of melanoma cell resistance to targeted treatment. Cancer Biol Med. 2021;19:56\u201373.","journal-title":"Cancer Biol Med"},{"key":"3861_CR67","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/genes11101214","volume":"11","author":"M Schmidt","year":"2020","unstructured":"Schmidt M, Loeffler-Wirth H, Binder H. Developmental scRNAseq trajectories in gene- and cell-state space\u2014the flatworm example. Genes. 2020;11:1214.","journal-title":"Genes"},{"key":"3861_CR68","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","volume":"41","author":"EM Parry","year":"2023","unstructured":"Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, et al. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023;41:1803\u201316.e1808.","journal-title":"Cancer Cell"},{"key":"3861_CR69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26:487\u2013504.","journal-title":"Clin Cancer Res"},{"key":"3861_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8:49.","journal-title":"Biomark Res"},{"key":"3861_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.trecan.2017.04.001","volume":"3","author":"M Arias","year":"2017","unstructured":"Arias M, Mart\u00ednez-Lostao L, Santiago L, Ferrandez A, Granville DJ, Pardo J. The untold story of granzymes in oncoimmunology: novel opportunities with old acquaintances. Trends Cancer. 2017;3:407\u201322.","journal-title":"Trends Cancer"},{"key":"3861_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122815","volume":"314","author":"N Liu","year":"2025","unstructured":"Liu N, Yan M, Lu C, Tao Q, Wu J, Zhou Z, et al. Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1\/CCL5 mediated M1 macrophage polarization in melanoma. Biomaterials. 2025;314:122815.","journal-title":"Biomaterials"},{"key":"3861_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4612375","volume":"2020","author":"Q Liu","year":"2020","unstructured":"Liu Q, Luo YW, Cao RY, Pan X, Chen XJ, Zhang SY, et al. Association between APOBEC3H-mediated demethylation and immune landscape in head and neck squamous carcinoma. Biomed Res Int. 2020;2020:4612375.","journal-title":"Biomed Res Int"},{"key":"3861_CR74","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618:598\u2013606.","journal-title":"Nature"},{"key":"3861_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00142-x","volume":"5","author":"X Zhu","year":"2021","unstructured":"Zhu X, Tian X, Ji L, Zhang X, Cao Y, Shen C, et al. A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. npj Precis Oncol. 2021;5:7.","journal-title":"npj Precis Oncol"},{"key":"3861_CR76","doi-asserted-by":"publisher","first-page":"12771","DOI":"10.3390\/ijms252312771","volume":"25","author":"J He","year":"2024","unstructured":"He J, Wang M, Wu D, Fu H, Shen X. Qualitative transcriptional signature for predicting the pathological response of colorectal cancer to FOLFIRI therapy. Int J Mol Sci. 2024;25:12771.","journal-title":"Int J Mol Sci"},{"key":"3861_CR77","doi-asserted-by":"crossref","unstructured":"Ji K, Jia H, Liu Z, Yu G, Wen R, Zhang T, et al. New insight in immunotherapy and combine therapy in colorectal cancer. Front Cell Dev Biol. 2025;12:2024.","DOI":"10.3389\/fcell.2024.1453630"},{"key":"3861_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4251\/wjgo.v15.i2.251","volume":"15","author":"JE Olguin","year":"2023","unstructured":"Olguin JE, Mendoza-Rodriguez MG, Sanchez-Barrera CA, Terrazas LI. Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? World J Gastrointest Oncol. 2023;15:251\u201367.","journal-title":"World J Gastrointest Oncol"},{"key":"3861_CR79","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1038\/nprot.2017.124","volume":"12","author":"J Ernst","year":"2017","unstructured":"Ernst J, Kellis M. Chromatin-state discovery and genome annotation with ChromHMM. Nat Protoc. 2017;12:2478\u201392.","journal-title":"Nat Protoc"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03861-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:53Z","timestamp":1783980233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03861-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":79,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026,8,4]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03861-2","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TK, NZ, AG, MT, SM, and LS were supported by a stipendium paid by Agenus Inc. (Lexington, MA, USA). GA, GM, SB, DC, and CD are current or former employees of Agenus, Inc. and may hold stock\/stock options. Agenus, Inc. supports bioinformatics research in the frame of its support-program for young scientists in Armenia. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}